Keith Watson

Keith Watson is a seasoned expert in regulatory affairs with extensive experience in the biotechnology and pharmaceutical sectors. Currently serving on the Scientific Advisory Board of NeoImmuneTech, Inc. since August 2022, Watson provides regulatory strategy guidance for the development of NT-17. As the Owner and Managing Director of KRW BioReg Solutions, Watson leverages 30 years of industry experience to support biological and biosimilar product development programs. Previous roles include Vice President of Regulatory Policy and Strategy at Celltrion Inc., where Watson led global regulatory efforts for a comprehensive biosimilar pipeline, and Director of Regulatory Affairs at AbbVie, guiding the company's biosimilar strategies. Watson has also contributed to significant regulatory initiatives while working with trade associations, including the IFPMA and EFPIA. With a PhD in Biochemistry from Imperial College London and a BSc in Applied Biochemistry from Liverpool John Moores University, Watson's career reflects a strong foundation in scientific research and regulatory expertise.